JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク,インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
US6884418B1
(en)
*
|
1989-08-04 |
2005-04-26 |
Berlex Laboratories, Inc. |
Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
|
CA2095141A1
(fr)
*
|
1990-11-05 |
1992-05-06 |
Ingegerd Hellstrom |
Therapie synergique allianmt des combinaisons d'anticorps antitumoraux et d'agents actifs biologiquement
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
JP2002515511A
(ja)
|
1998-05-15 |
2002-05-28 |
イムクローン システムズ インコーポレイティド |
放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
|
US20080096236A1
(en)
*
|
1998-08-25 |
2008-04-24 |
Binax, Inc. |
Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
|
US9134303B1
(en)
|
1998-08-25 |
2015-09-15 |
Alere Scarborough, Inc. |
ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
|
US6824997B1
(en)
|
1998-09-18 |
2004-11-30 |
Binax, Inc. |
Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
|
IL146480A0
(en)
*
|
1999-05-14 |
2002-07-25 |
Imclone Systems Inc |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
TWI269654B
(en)
|
1999-09-28 |
2007-01-01 |
Baxter Healthcare Sa |
N-substituted indole-3-glyoxylamide compounds having anti-tumor action
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
US20020103345A1
(en)
*
|
2000-05-24 |
2002-08-01 |
Zhenping Zhu |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
EP1170011A1
(fr)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Nouvelle utilisation des inhibiteurs de facteur de croissance épidermique
|
AU2001295002B2
(en)
*
|
2000-08-09 |
2007-05-31 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
DE60134679D1
(de)
*
|
2000-10-20 |
2008-08-14 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische Heterozyklen
|
US7906492B2
(en)
*
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US7507724B2
(en)
*
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
JP4660067B2
(ja)
|
2001-04-24 |
2011-03-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗血管新生剤とTNFαとを用いる組合せ療法
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
US7589180B2
(en)
|
2001-05-11 |
2009-09-15 |
Abbott Laboratories Inc. |
Specific binding proteins and uses thereof
|
KR20090125840A
(ko)
*
|
2001-06-13 |
2009-12-07 |
젠맵 에이/에스 |
표피 성장 인자 수용체 (egfr)에 대한 인간 모노클로날 항체
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
CA2452058A1
(fr)
*
|
2001-06-26 |
2003-01-09 |
Imclone Systems Incorporated |
Anticorps bispecifiques se liant aux recepteurs vegf
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
WO2004058821A2
(fr)
*
|
2002-12-27 |
2004-07-15 |
Domantis Limited |
Ligand
|
DK1399484T3
(da)
*
|
2001-06-28 |
2010-11-08 |
Domantis Ltd |
Dobbelt-specifik ligand og anvendelse af denne
|
DE10133394A1
(de)
*
|
2001-07-13 |
2003-01-30 |
Merck Patent Gmbh |
Flüssige Formulierung enthaltend Cetuximab
|
DK1916001T3
(da)
|
2002-03-04 |
2011-07-18 |
Imclone Llc |
KDR-specifikke humane antistoffer og anvendelser deraf
|
AU2003211594A1
(en)
*
|
2002-03-05 |
2003-09-16 |
Eisai Co., Ltd. |
Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
|
US7217796B2
(en)
*
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
ATE328906T1
(de)
*
|
2002-06-28 |
2006-06-15 |
Domantis Ltd |
Dual-specifische liganden mit erhöhter halbwertszeit
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
ES2533963T3
(es)
*
|
2002-10-10 |
2015-04-16 |
Merck Patent Gmbh |
Composiciones farmacéuticas dirigidas a receptores Erb-B1
|
US20040147428A1
(en)
*
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
TWI229650B
(en)
*
|
2002-11-19 |
2005-03-21 |
Sharp Kk |
Substrate accommodating tray
|
US7994159B2
(en)
|
2003-03-10 |
2011-08-09 |
Eisai R&D Management Co., Ltd. |
c-Kit kinase inhibitor
|
EP1622941A2
(fr)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Procede de production d'un anticorps contre le recepteur du facteur de croissance epidermique
|
US7425328B2
(en)
*
|
2003-04-22 |
2008-09-16 |
Purdue Pharma L.P. |
Tissue factor antibodies and uses thereof
|
ES2527871T3
(es)
|
2003-05-01 |
2015-02-02 |
Imclone Llc |
Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
|
US20070036795A1
(en)
|
2003-06-09 |
2007-02-15 |
Samuel Waksal |
Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
|
CN104059147A
(zh)
|
2003-06-27 |
2014-09-24 |
艾默根佛蒙特有限公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
ATE485307T1
(de)
|
2003-11-07 |
2010-11-15 |
Ablynx Nv |
Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
|
JP4303726B2
(ja)
*
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
PE20050928A1
(es)
*
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
US7767792B2
(en)
*
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
PL1735348T3
(pl)
|
2004-03-19 |
2012-11-30 |
Imclone Llc |
Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
|
NZ550665A
(en)
|
2004-04-09 |
2010-05-28 |
Chugai Pharmaceutical Co Ltd |
Novel water-soluble prodrugs of camptothecin derivatives
|
AU2005265163B2
(en)
|
2004-06-18 |
2009-10-01 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
US8772269B2
(en)
*
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
US8969379B2
(en)
|
2004-09-17 |
2015-03-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
|
WO2006042313A2
(fr)
*
|
2004-10-12 |
2006-04-20 |
Imclone Systems Incorporated |
Methode de traitement destinee a combattre l'accumulation de liquide sereux dans des cavites sereuses du corps
|
JP2008519757A
(ja)
*
|
2004-11-12 |
2008-06-12 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
抗egfr抗体の固形物
|
JPWO2006090930A1
(ja)
*
|
2005-02-28 |
2008-07-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホンアミド化合物の新規併用
|
US20060233810A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Yaolin Wang |
Methods and compositions for treating or preventing cancer
|
US20090214562A1
(en)
*
|
2005-05-03 |
2009-08-27 |
Karel Steven J |
Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
|
CA2611149A1
(fr)
|
2005-06-15 |
2006-12-28 |
Schering Corporation |
Formulation d'anticorps stable
|
CA2678008C
(fr)
|
2005-06-17 |
2013-07-30 |
Imclone Systems Incorporated |
Antagonistes de recepteur pour le traitement de cancer osseux metastatique
|
JP5066446B2
(ja)
*
|
2005-08-01 |
2012-11-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を予測する方法
|
JP2007039346A
(ja)
*
|
2005-08-01 |
2007-02-15 |
Yokohama Kokusai Bio Kenkyusho:Kk |
腫瘍特異的抗体と結合したタキソイド誘導体及びその製造方法
|
EP1925676A4
(fr)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
Procédé d'analyse de l' effet d 'un inhibiteur de vascularisation
|
TW200744603A
(en)
|
2005-08-22 |
2007-12-16 |
Chugai Pharmaceutical Co Ltd |
Novel anticancer concomitant drug
|
CA2620594C
(fr)
*
|
2005-09-01 |
2012-08-21 |
Eisai R&D Management Co., Ltd. |
Composition pharmaceutique dotee d'une meilleure capacite a se desintegrer
|
EP1934599A1
(fr)
|
2005-10-11 |
2008-06-25 |
Merck Patent GmbH |
Modulation dépendante d'egfr de l'expression des chimiokines et influence sur le traitement et le diagnostic des tumeurs et sur leurs effets secondaires
|
CN101316590B
(zh)
*
|
2005-11-07 |
2011-08-03 |
卫材R&D管理有限公司 |
血管生成抑制剂和c-kit激酶抑制剂的组合使用
|
US20090306101A1
(en)
*
|
2005-11-11 |
2009-12-10 |
Flavio Solca |
Combination treatment of cancer comprising egfr/her2 inhibitors
|
US8404697B2
(en)
|
2005-11-11 |
2013-03-26 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
EP1964837A4
(fr)
*
|
2005-11-22 |
2010-12-22 |
Eisai R&D Man Co Ltd |
Agent antitumeur pour myelomes multiples
|
EA200801170A1
(ru)
*
|
2005-12-01 |
2008-12-30 |
Домантис Лимитед |
Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
|
EA015173B1
(ru)
|
2006-01-04 |
2011-06-30 |
Мерк Патент Гмбх |
Комбинированная терапия с использованием антител к egfr и her2
|
US8323644B2
(en)
*
|
2006-01-17 |
2012-12-04 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
CA2650953A1
(fr)
|
2006-05-03 |
2007-11-15 |
Bayer Schering Pharma Aktiengesellschaft |
Combinaison d'un anticorps l19-sip anti domaine ed-b de la fibronectine et d'un anticorps anti-egfr
|
ES2556173T3
(es)
*
|
2006-05-18 |
2016-01-13 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral para un cáncer de tiroides
|
EP2044939A1
(fr)
*
|
2006-06-29 |
2009-04-08 |
Eisai R&D Management Co., Ltd. |
Agent thérapeutique contre la fibrose hépatique
|
CA2655997A1
(fr)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Biomarqueur igfbp2
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
MX338185B
(es)
*
|
2007-01-25 |
2016-04-05 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
EP2119707B1
(fr)
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
|
WO2008104183A2
(fr)
*
|
2007-03-01 |
2008-09-04 |
Symphogen A/S |
Compositions d'anticorps recombinants dirigés contre le récepteur du facteur de croissance épidermique
|
CN101679511A
(zh)
*
|
2007-06-06 |
2010-03-24 |
杜门蒂斯有限公司 |
多肽、抗体可变域和拮抗剂
|
KR100883430B1
(ko)
*
|
2007-06-13 |
2009-02-12 |
한국생명공학연구원 |
혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
|
US20100322939A1
(en)
*
|
2007-06-21 |
2010-12-23 |
Genmab A/S |
Novel methods for treating egfr-associated tumors
|
EP2188311B1
(fr)
*
|
2007-08-14 |
2016-10-05 |
Ludwig Institute for Cancer Research Ltd. |
Anticorps monoclonal 175 ciblant le récepteur egf et dérivées et utilisations de ceux-ci
|
EP3492488A1
(fr)
|
2007-08-22 |
2019-06-05 |
The Regents of The University of California |
Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci
|
CA2715080C
(fr)
|
2007-09-28 |
2021-09-28 |
Intrexon Corporation |
Constructions et bioreacteurs de commutation de gene theapeutique destines a l'expression de molecules biotherapeutiques, et utilisation de ceux-ci
|
EP2212432A4
(fr)
*
|
2007-10-22 |
2011-10-19 |
Schering Corp |
Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
|
CN101848895B
(zh)
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
AU2009210098B2
(en)
*
|
2008-01-29 |
2013-06-13 |
Eisai R & D Management Co., Ltd. |
Combined use of angiogenesis inhibitor and taxane
|
ES2639857T3
(es)
|
2008-02-11 |
2017-10-30 |
Cure Tech Ltd. |
Anticuerpos monoclonales para el tratamiento del tumor
|
CA2716851A1
(fr)
*
|
2008-03-06 |
2009-09-11 |
Genentech, Inc. |
Therapie combinee par des antagonistes de c-met et egfr
|
AR071891A1
(es)
*
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
AU2009287163B2
(en)
|
2008-08-29 |
2014-11-13 |
Les Laboratoires Servier |
Recombinant anti-Epidermal Growth Factor Receptor antibody compositions
|
EP3216874A1
(fr)
*
|
2008-09-05 |
2017-09-13 |
TOMA Biosciences, Inc. |
Procédés pour la stratification et l'annotation des options de traitement médicamenteux contre le cancer
|
CN102482347B
(zh)
|
2009-01-12 |
2017-04-26 |
希托马克斯医疗有限责任公司 |
修饰抗体组合物及其制备和使用方法
|
CN102481341B
(zh)
|
2009-02-23 |
2017-05-17 |
希托马克斯医疗有限公司 |
蛋白原及其使用方法
|
SG174378A1
(en)
|
2009-03-20 |
2011-10-28 |
Genentech Inc |
Bispecific anti-her antibodies
|
US9545381B2
(en)
|
2009-07-06 |
2017-01-17 |
Boehringer Ingelheim International Gmbh |
Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
|
US20120288495A1
(en)
|
2009-07-22 |
2012-11-15 |
Biothera, Inc. |
Therapeutic compositions and methods
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
AU2010310786B2
(en)
|
2009-10-23 |
2014-03-27 |
Eli Lilly And Company |
AKT inhibitors
|
WO2011107664A1
(fr)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Méthode de sélection de patients pour un traitement par un inhibiteur de l'egfr
|
EP2371369A1
(fr)
|
2010-04-01 |
2011-10-05 |
Institut Gustave Roussy (IGR) |
Inhibiteur EGFR et agent antiviral pour une utilisation simultanée, séparée ou séquentielle pour le traitement, la prévention et/ou la palliation du cancer
|
WO2011156617A2
(fr)
|
2010-06-09 |
2011-12-15 |
Aveo Pharmaceuticals, Inc. |
Anticorps anti-egfr
|
US9012458B2
(en)
|
2010-06-25 |
2015-04-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
WO2012009705A1
(fr)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Complexes liant ang-2 et leurs utilisations
|
US9464136B2
(en)
|
2010-08-20 |
2016-10-11 |
Massachusetts Institute Of Technology |
Antibody-based constructs directed against tyrosine kinase receptors
|
EP3572528A1
(fr)
|
2010-09-24 |
2019-11-27 |
The Board of Trustees of the Leland Stanford Junior University |
Capture directe, amplification et séquençage d'adn cible à l'aide d'amorces immobilisées
|
JP6243737B2
(ja)
|
2010-10-27 |
2017-12-06 |
ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク |
E−カドヘリンの可溶性細胞外ドメインを標的とする組成物および癌治療のための関連方法
|
SG189929A1
(en)
|
2010-10-29 |
2013-06-28 |
Immunogen Inc |
Novel egfr-binding molecules and immunoconjugates thereof
|
EA201390575A1
(ru)
|
2010-10-29 |
2014-01-30 |
Иммьюноджен, Инк. |
Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
|
JP2014503500A
(ja)
|
2010-11-18 |
2014-02-13 |
シンタ ファーマスーティカルズ コーポレーション |
低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
|
US8628773B2
(en)
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
WO2012144463A1
(fr)
|
2011-04-18 |
2012-10-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Agent thérapeutique pour les tumeurs
|
WO2012166899A2
(fr)
|
2011-06-03 |
2012-12-06 |
Eisai R&D Management Co., Ltd. |
Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
|
EP3559049A4
(fr)
|
2011-10-28 |
2019-12-04 |
Teva Pharmaceuticals Australia Pty Ltd |
Produits de recombinaison de polypeptide et utilisations de ceux-ci
|
CN104066481A
(zh)
|
2011-11-21 |
2014-09-24 |
伊缪诺金公司 |
利用egfr抗体细胞毒性剂缀合物治疗抗egfr疗法的肿瘤的方法
|
EP2879712B1
(fr)
|
2012-07-31 |
2018-04-25 |
Crown Bioscience, Inc. (Taicang) |
Marqueurs histologiques pour l'identification de patients atteints d'un carcinome du poumon non à petites cellules pour le traitement par un médicament anti-egfr
|
AU2013299841B8
(en)
|
2012-08-07 |
2017-01-05 |
Array Biopharma Inc. |
Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
|
CN104837502B
(zh)
|
2012-10-12 |
2018-08-10 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
MX2015007719A
(es)
|
2012-12-21 |
2015-09-07 |
Sykehuset Sørlandet Hf |
Terapia dirigida del receptor del factor de crecimiento epidermico (egfr) de trastornos neurologicos y dolor.
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
MX2015010427A
(es)
|
2013-02-13 |
2016-03-17 |
Lab Francais Du Fractionnement |
Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos.
|
BR112015019348A2
(pt)
|
2013-02-13 |
2017-08-22 |
Lab Francais Du Fractionnement |
Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
|
JP6444902B2
(ja)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン及びその結合体
|
AU2013388126B2
(en)
|
2013-04-29 |
2019-03-07 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
RU2646098C2
(ru)
*
|
2013-04-30 |
2018-03-01 |
Интас Фармасьютикалс Лтд |
Новый способ клонирования, экспрессии и очистки для получения ранибизумаба
|
KR102204279B1
(ko)
|
2013-05-14 |
2021-01-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
|
RU2675824C2
(ru)
|
2013-09-11 |
2018-12-25 |
Игл Байолоджикс, Инк. |
Жидкие белковые составы, содержащие ионные жидкости
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
RS63559B1
(sr)
|
2014-08-28 |
2022-10-31 |
Eisai R&D Man Co Ltd |
Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
SG11201702614SA
(en)
|
2014-10-01 |
2017-04-27 |
Eagle Biolog Inc |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
US10385380B2
(en)
|
2014-10-02 |
2019-08-20 |
The Regents Of The University Of California |
Personalized protease assay to measure protease activity in neoplasms
|
AU2015341081A1
(en)
|
2014-10-28 |
2017-06-08 |
Merck Patent Gmbh |
Methods for non-covalent Fc-domain-containing protein display on the surface of cells and methods of screening thereof
|
KR102639037B1
(ko)
|
2014-10-29 |
2024-02-20 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
인터페론 α2b 변이체
|
CA2963274C
(fr)
|
2014-12-05 |
2024-01-30 |
Avidbiotics Corp. |
Fragments variables inserables d'anticorps et domaines a1-a2 modifies de ligands nkg2d
|
PL3263106T3
(pl)
|
2015-02-25 |
2024-04-02 |
Eisai R&D Management Co., Ltd. |
Sposób tłumienia goryczy pochodnej chinoliny
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
CN105237638A
(zh)
*
|
2015-10-26 |
2016-01-13 |
无锡傲锐东源生物科技有限公司 |
抗egfr蛋白单克隆抗体杂交瘤细胞及其产生的抗egfr单克隆抗体和应用
|
RU2018141777A
(ru)
|
2016-04-28 |
2020-05-28 |
Биомюнё Фармасьютикалз |
Биспецифичные антитела, нацеленные на egfr и her2
|
HUE060653T2
(hu)
|
2016-06-03 |
2023-04-28 |
Array Biopharma Inc |
Gyógyászati kombinációk
|
KR20190019091A
(ko)
|
2016-06-24 |
2019-02-26 |
사이포스 바이오사이언시스 인코포레이티드 |
항체의 삽입가능 가변 단편 및 nkg2d 리간드의 변형된 a1-a2 도메인
|
EP3525829A1
(fr)
|
2016-10-11 |
2019-08-21 |
Medimmune Limited |
Conjugués anticorps-médicament associés à des agents thérapeutiques à médiation immunitaire
|
CN106800599B
(zh)
*
|
2016-12-05 |
2021-03-23 |
中国人民解放军第二军医大学 |
抗人EGFR和Notch多特异性抗体、其制备方法及用途
|
BR112019014127A2
(pt)
|
2017-02-08 |
2020-02-11 |
Eisai R&D Management Co., Ltd. |
Composição farmacêutica para tratamento de tumores
|
US10646569B2
(en)
|
2017-05-16 |
2020-05-12 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
CA3019207A1
(fr)
|
2017-09-28 |
2019-03-28 |
The Governing Council Of The University Of Toronto |
Methodes et compositions empechant le signalement de mutation d'egfr
|
CN113286616A
(zh)
|
2018-05-23 |
2021-08-20 |
Adc治疗有限公司 |
分子佐剂
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
SG11202104900SA
(en)
|
2018-11-20 |
2021-06-29 |
Univ Cornell |
Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
|
WO2020200944A1
(fr)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Procédé de production d'anticorps multispécifiques à liaison avide
|
WO2020225552A1
(fr)
|
2019-05-06 |
2020-11-12 |
Medimmune Limited |
Combinaison de monalizumab, de durvalumab, de chimiothérapie et de bévacizumab ou de cétuximab pour le traitement du cancer colorectal
|
WO2022079211A1
(fr)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugués
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
AU2022250323A1
(en)
|
2021-03-31 |
2023-11-09 |
Nihon Medi-Physics Co., Ltd. |
Radioactive complex of anti-egfr antibody, and radiopharmaceutical
|
CA3222462A1
(fr)
|
2021-06-14 |
2022-12-22 |
Tania Crombet Ramos |
Utilisation d'anticorps monoclonaux contre le recepteur du facteur de croissance epidermique dans le traitement de patients presentant une insuffisance respiratoire aigue hypoxemiqu
|
WO2023288267A1
(fr)
|
2021-07-14 |
2023-01-19 |
2Seventy Bio, Inc. |
Récepteurs de lymphocytes t modifiés fusionnés à des domaines de liaison d'anticorps
|
WO2023166098A1
(fr)
|
2022-03-02 |
2023-09-07 |
Biomunex Pharmaceuticals |
Anticorps bispécifiques se liant à her-3 et à her-2 ou egfr
|
WO2023196997A2
(fr)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Récepteur multipartite et complexes de signalisation
|